You are a drug company executive who have decided that a new drug development strategy for neurodegenerative disorders such as Alzheimer’s disease (AD) is to target the ageing process.  Prepare a report to the board of directors to convince them to approve this change in direction. This report should include a discussion on:

A. why you have chosen AD as the neurodegenerative disorder for this campaign (3 marks)

B. the limitations of disease-modifying strategies that are currently in clinical trials for the treatment of AD (3 marks)

C. the scientific evidence behind such a strategy (3 marks)

D. your choice of target for this campaign (3 marks)